Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 3Completed 3Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other neoplasm 4Breast 4Gastrointestinal 3Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Dermatologic 1

Conditions

Adenomatous Polyposis Coli 2Rectal Neoplasms 1Precancerous Conditions 1Colonic Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Sulindac × Gastrointestinal × Clear all
NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00335504 2017-02-15

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
85 enrolled 10 charts
GastrointestinalOther neoplasm

Colonic Neoplasms, Precancerous Conditions, Rectal Neoplasms

NCT01187901 2016-06-17

FAPEST

University of Utah

Phase 2 Completed
92 enrolled 11 charts
Gastrointestinal

Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡